You are here: Industry Insights > Gilead Sciences

News List

Gilead taps gene editors at Precision BioSciences for hepatitis B cure development fiercebiotech
September 14, 2018
Precision’s platform is derived from a natural enzyme that can target specific gene locations and insert or delete DNA, disrupting sequences.
AbbVie surprised investors with its hepatitis C success. Will it last? biopharmadive
August 13, 2018
By the time AbbVie brought its first drug for hepatitis C to market, in December 2014, it was already too late.
Gilead's Truvada for PrEP can reduce HIV rates, but activists decry unequal access fiercepharma
July 26, 2018
Groups around the world are working hard to develop HIV vaccines, but in the meantime, Gilead Sciences reports that Truvada can significantly reduce the rate of new infections when used as a pre-exposure prophylaxis.
CDA approves Gilead’s chronic hepatitis C virus infection drug biospectrumasia
June 01, 2018
HCV is the fourth-most commonly reported infectious disease in China, with approximately 10 million people infected. HCV genotypes 1, 2, 3 and 6 account for more than 96 percent of all cases.
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents drugs
May 17, 2018
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Gilead Sciences: Investors Are Betting On A Better 2019 forbes
February 08, 2018
The hepatitis C virus. For years, U.S. drug maker Gilead Sciences has been hobbled by weakening sales of drugs for this liver-damaging viral infection.
Gilead to Acquire Kite Pharma for $11.9B contractpharma
September 05, 2017
Gilead Sciences has entered an agreement to acquire Kite Pharma, a cell therapy company headquartered in Santa Monica, CA, for approximately $11.9 billion. The transaction, subject to customary closing conditions, is expected to close 4Q17.
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight fiercepharma
August 30, 2017
Gilead announced an $11.9 purchase of Kite Pharma on Monday, picking up the promising CAR-T drug Axi-Cel.
Gilead Sciences to buy Kite Pharma for $11.9bn pharmaceutical-technology
August 30, 2017
Biopharmaceutical company Gilead Sciences has entered a definitive agreement to acquire US-based Kite Pharma for approximately $11.9bn.
Growth-hungry Gilead acquires Kite at $12B for its nearly approved CAR-T treatment expressbpd
August 29, 2017
Gilead Sciences will buy Kite Pharma for nearly $12 billion, when Kite's cutting-edge CAR-T treatment is nearly approved.

Previous page 1 2 3 4 5 Next page